Company: MBIO
Filing Date: 2025-12-03
Form Type: DEF 14A
Source: 0001104659-25-118122
Chunk: 11

Company: MUSTANG BIO, INC.
Filing Date: 2025-12-03
Form: DEF 14A
Chunk 11
---
 | ​ | ​ | ​ |
| Lindsay A. Rosenwald, M.D. |   |  70 |   | Director                                                                         | ​ |           2015 | ​ | ​ | ​ |
| Michael J. Zelefsky, M.D.  |   |  65 |   | Director                                                                         | ​ |           2017 | ​ | ​ | ​ |

The Board does not have a formal policy regarding the separation of the roles of Chief Executive Officer and Chairman of the Board, as the Board believes that it is in the best interests of the Company to make that determination based on the direction of the Company and the current membership of the Board. The Board has determined that having a director who is also the chief executive officer serve as the Chairman is not in the best interest of the Company’s stockholders at this time. The Board held 21 meetings during the fiscal year ended December 31, 2024. Each incumbent director of the Company attended at least 75% of the aggregate of the total number of board meetings held during the period that director served, and the total number of meetings held by all board committees on which that director served during the period of that director’s committee service. Further, all directors attended last year’s annual meeting. Mustang has a risk management program overseen by Manuel Litchman, M.D., our President, Chief Executive Officer and Interim Chief Financial Officer. Dr. Litchman and management identify material risks and prioritize them for our Board. Our Board regularly reviews information regarding our credit, liquidity, operations, and compliance as well as the risks associated with each. The following biographies set forth the names of our directors and director nominees, their ages, the year in which they first became directors, their positions with us, their principal occupations and employers for at least the past five years, any other directorships held by them during the past five years in companies that are subject to the reporting requirements of the Securities Exchange Act of 1934 (the “Exchange Act”), or any company registered as an investment company under the Investment Company Act of 1940, as well as additional information, all of which we believe sets forth each director nominee’s qualifications to serve on the Board. There is no family relationship between and among any of our executive officers or directors. On April 7, 2017, we entered into an Executive Employment Agreement with Dr. Litchman, pursuant to which, among other things, the Company agreed to use its best efforts to cause Dr. L